Skip to main content

Table 1 IGFBP7 expression, mutation and genotyping analyses relative to EOC cell lines features and growth characteristics

From: Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome

Cell lines Histopathology Grade Stage Source Age TP53mutation status* Growth in soft agar* Spheroid formation* Tumour formation in nude mouse* IGFBP7mutation GenotypeIGFBP7locus IGFBP7methylation IGFBP7transcript expression IGFBP7 protein detection in total cell lysate
Subcutaneous Intraperitoneal
TOV2223G Serous papillary cystadenocarcinoma 3 III-C Tumor 89 Positive Yes No No No No LOH Yes Low No
OV1946 Serous papillary cystadenocarcinoma 3 III-C Ascites 75 Positive Yes Semi-compact No Yes No LOH No Low No
TOV1946 Serous papillary cystadenocarcinoma 3 III-C Tumor 75 Positive Yes Aggregate No Yes No LOH No Low No
TOV81D Serous papillary adenocarcinoma 1-2 III-C Tumor 66 Negative No No No No No HET No High High
TOV112D Endometrioid carcinoma 3 III-C Tumor 42 Positive Yes Yes Yes Yes No LOH Yes No No
TOV21G Clear cell carcinoma 3 III Tumor 62 Negative Yes Yes Yes Yes No HET No High Low
OV90 Adenocarcinoma 3 III-C Ascites 64 Positive Yes Yes Yes Yes No AI No Low No
  1. *From Provencher et al. [19]; Ouellet et al. [46]; Cody et al [15]. n/d: not determined, LOH: Loss of heterozygosity, HET: heterozygote, AI: allelic imbalance.